TY - JOUR
T1 - Emerging biomarkers in kidney transplantation and challenge of clinical implementation
AU - Westphal, Scott G.
AU - Mannon, Roslyn B.
N1 - Publisher Copyright:
Copyright ß 2021 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Purpose of review Despite improvement in short-term outcomes after kidney transplantation, long-term outcomes remain suboptimal. Conventional biomarkers are limited in their ability to reliably identify early immunologic and nonimmunologic injury. Novel biomarkers are needed for noninvasive diagnosis of subclinical injury, prediction of response to treatment, and personalization of the care of kidney transplant recipients. Recent findings Recent biotechnological advances have led to the discovery of promising molecular biomarker candidates. However, translating potential biomarkers from bench to clinic is challenging, and many potential biomarkers are abandoned prior to clinical implementation. Despite these challenges, several promising urine, blood, and tissue novel molecular biomarkers have emerged and are approaching incorporation into clinical practice. Summary This article highlights the challenges in adopting biomarker-driven posttransplant management and reviews several promising emerging novel biomarkers that are approaching clinical implementation.
AB - Purpose of review Despite improvement in short-term outcomes after kidney transplantation, long-term outcomes remain suboptimal. Conventional biomarkers are limited in their ability to reliably identify early immunologic and nonimmunologic injury. Novel biomarkers are needed for noninvasive diagnosis of subclinical injury, prediction of response to treatment, and personalization of the care of kidney transplant recipients. Recent findings Recent biotechnological advances have led to the discovery of promising molecular biomarker candidates. However, translating potential biomarkers from bench to clinic is challenging, and many potential biomarkers are abandoned prior to clinical implementation. Despite these challenges, several promising urine, blood, and tissue novel molecular biomarkers have emerged and are approaching incorporation into clinical practice. Summary This article highlights the challenges in adopting biomarker-driven posttransplant management and reviews several promising emerging novel biomarkers that are approaching clinical implementation.
KW - Acute rejection
KW - Biomarkers
KW - Kidney transplantation
KW - Noninvasive monitoring
UR - http://www.scopus.com/inward/record.url?scp=85122278221&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122278221&partnerID=8YFLogxK
U2 - 10.1097/MOT.0000000000000941
DO - 10.1097/MOT.0000000000000941
M3 - Review article
C2 - 34939960
AN - SCOPUS:85122278221
SN - 1087-2418
VL - 27
SP - 15
EP - 21
JO - Current opinion in organ transplantation
JF - Current opinion in organ transplantation
IS - 1
ER -